688506 百利天恒
已收盘 02-12 15:00:01
资讯
新帖
简况
2月10日百利天恒涨6.14%，中欧医疗健康混合A基金重仓该股
证券之星 · 02-10 16:33
2月10日百利天恒涨6.14%，中欧医疗健康混合A基金重仓该股
每周股票复盘：百利天恒（688506）拟发不超100亿债务融资工具
证券之星 · 02-08
每周股票复盘：百利天恒（688506）拟发不超100亿债务融资工具
百利天恒回购32万股 金额9985万元
财中社 · 02-03
百利天恒回购32万股 金额9985万元
百利天恒目标价涨幅近376% 金辰股份评级被调低丨券商评级观察
21世纪经济报道 · 02-02
百利天恒目标价涨幅近376% 金辰股份评级被调低丨券商评级观察
医保数据发布再升级；多家药企发布业绩预告
21世纪经济报道 · 02-02
医保数据发布再升级；多家药企发布业绩预告
股市必读：百利天恒（688506）预计2025年全年营业收入25亿元
证券之星 · 02-02
股市必读：百利天恒（688506）预计2025年全年营业收入25亿元
百利天恒：预计2025年净亏损11亿元 同比转亏
每日经济新闻 · 01-30
百利天恒：预计2025年净亏损11亿元 同比转亏
23股获推荐 百利天恒目标价涨幅超300%丨券商评级观察
21世纪经济报道 · 01-27
23股获推荐 百利天恒目标价涨幅超300%丨券商评级观察
百利天恒（688506）披露召开2026年第一次临时股东会通知，1月23日股价下跌0.38%
证券之星 · 01-23
百利天恒（688506）披露召开2026年第一次临时股东会通知，1月23日股价下跌0.38%
广发基金吴兴武旗下广发保健A年报最新持仓，重仓百利天恒
证券之星 · 01-22
广发基金吴兴武旗下广发保健A年报最新持仓，重仓百利天恒
1月21日百利天恒现269.67万元大宗交易
证券之星 · 01-21
1月21日百利天恒现269.67万元大宗交易
百利天恒iza-bren用于治疗复发性或转移性食管鳞癌的药品上市申请获得受理
北京商报 · 01-20
百利天恒iza-bren用于治疗复发性或转移性食管鳞癌的药品上市申请获得受理
贵州茅台等191股获推荐，百利天恒目标价涨幅超300%丨券商评级观察
南方财经网 · 01-19
贵州茅台等191股获推荐，百利天恒目标价涨幅超300%丨券商评级观察
每周股票复盘：百利天恒（688506）股东OAP拟减持不超1%股份
证券之星 · 01-18
每周股票复盘：百利天恒（688506）股东OAP拟减持不超1%股份
百利天恒股东OAP III(HK)Limited拟减持不超1%公司股份
财中社 · 01-16
百利天恒股东OAP III(HK)Limited拟减持不超1%公司股份
每周股票复盘：百利天恒（688506）EGFR×HER3双抗ADC纳入优先审评
证券之星 · 01-11
每周股票复盘：百利天恒（688506）EGFR×HER3双抗ADC纳入优先审评
百利天恒：首次回购14858股
南方财经网 · 01-08
百利天恒：首次回购14858股
百利天恒：关于取得金融机构股票回购专项贷款承诺函的公告
证券日报 · 01-07
百利天恒：关于取得金融机构股票回购专项贷款承诺函的公告
百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于治疗复发性或转移性食管鳞癌被纳入优先审评程序
智通财经 · 01-06
百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于治疗复发性或转移性食管鳞癌被纳入优先审评程序
百利天恒（688506）2.98亿股限售股将于1月6日解禁，占总股本72.2%
证券之星 · 01-06
百利天恒（688506）2.98亿股限售股将于1月6日解禁，占总股本72.2%
加载更多
公司概况
公司名称：
四川百利天恒药业股份有限公司
所属行业：
医药制造业
上市日期：
2023-01-06
主营业务：
四川百利天恒药业股份有限公司的主营业务是创新生物药业务板块和化药制剂、中成药制剂业务板块。公司的主要产品是丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。
发行价格：
24.70
{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":289.4,"timestamp":1770879601000,"preClose":292,"halted":0,"volume":1393448,"delay":0,"changeRate":-0.0089,"floatShares":401000000,"shares":413000000,"eps":-2.0646,"marketStatus":"已收盘","change":-2.6,"latestTime":"02-12 15:00:01","open":293.8,"high":293.8,"low":283.91,"amount":403000000,"amplitude":0.0339,"askPrice":289.62,"askSize":3,"bidPrice":289.4,"bidSize":17,"shortable":0,"etf":0,"ttmEps":-2.0646,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770946200000},"marketStatusCode":5,"adr":0,"adjPreClose":292,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770859800000,1770867000000],[1770872400000,1770879600000]],"highLimit":321.2,"lowLimit":262.8,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":412873817,"isCdr":false,"pbRate":16.66,"roa":"--","roe":"--","epsLYR":9.25,"committee":0.64486,"marketValue":119486000000,"turnoverRate":0.0035,"status":1,"afterMarket":{"amount":0,"volume":0,"close":289.4,"buyVolume":0,"sellVolume":0,"time":1770881637558,"indexStatus":"已收盘 02-12 15:30:00","preClose":292},"hkstockBrief":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1770883200000,"preClose":0,"halted":7,"volume":0,"delay":0,"premium":"-100.00"},"floatMarketCap":116049000000},"requestUrl":"/m/hq/s/688506","defaultTab":"news","newsList":[{"id":"2610612060","title":"2月10日百利天恒涨6.14%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610612060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610612060?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:33","pubTimestamp":1770712390,"startTime":"0","endTime":"0","summary":"证券之星消息，2月10日百利天恒涨6.14%，收盘报288.0元，换手率0.85%，成交量3.42万手，成交额9.72亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共131家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为138.43亿元，最新净值1.7986，较上一交易日上涨0.17%，近一年上涨16.05%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000026074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159760","688506","91194","02615","BK0239"],"gpt_icon":0},{"id":"2609152376","title":"每周股票复盘：百利天恒（688506）拟发不超100亿债务融资工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2609152376","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609152376?lang=zh_cn&edition=full","pubTime":"2026-02-08 01:33","pubTimestamp":1770485590,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，百利天恒报收于281.0元，较上周的277.75元上涨1.17%。本周，百利天恒2月5日盘中最高价报287.69元。本周关注点公司公告汇总：拟申请注册发行规模不超过人民币100亿元的债务融资工具。四川百利天恒药业股份有限公司于2025年12月30日召开董事会，审议通过以集中竞价交易方式回购公司股份的方案，回购期限为2025年12月30日至2026年12月29日，拟回购金额为10,000万元至20,000万元，回购价格不超过546元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","02615","688506"],"gpt_icon":0},{"id":"2608822501","title":"百利天恒回购32万股 金额9985万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608822501","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608822501?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:17","pubTimestamp":1770113866,"startTime":"0","endTime":"0","summary":"2月3日，百利天恒（688506）发布公告，截至2026年1月31日，公司已回购32万股，占总股本的0.08%，回购资金总额为9985万元，回购价格区间为279.72元/股至345.24元/股。2025年前三季度，百利天恒实现收入20.66亿元，归母净利润-4.95亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602033640244377.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","688506","91194","BK0239"],"gpt_icon":0},{"id":"2608838285","title":"百利天恒目标价涨幅近376% 金辰股份评级被调低丨券商评级观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2608838285","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608838285?lang=zh_cn&edition=full","pubTime":"2026-02-02 09:19","pubTimestamp":1769995154,"startTime":"0","endTime":"0","summary":"南财投研通数据显示，1月26日至2月1日，券商给予上市公司目标价共103次，按最新收盘价计算，目标价涨幅排名居前的公司有百利天恒、泽璟制药、长城汽车，目标价涨幅分别为375.97%、88.56%、83.66%，前两者分别属于化学制药行业，后者属于乘用车行业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638055674.html","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638055674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","603396","688506","91194"],"gpt_icon":0},{"id":"2608887409","title":"医保数据发布再升级；多家药企发布业绩预告","url":"https://stock-news.laohu8.com/highlight/detail?id=2608887409","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608887409?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:04","pubTimestamp":1769990666,"startTime":"0","endTime":"0","summary":"政策动向医保数据发布再升级2月1日，国家医保局官微发文称，医保数据工作组是医保部门的一项创新性工作。数据发布活动组织一年多以来，各地发布内容不断丰富，发布形式更加多样，一些地方基于按病种付费改革开展病种专题分析，为疾病诊疗资源消耗“画像”，为医疗机构提供更加具体、好用的管理工具。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638025174.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638025174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","LU1223082519.USD","BK1161","BK0196","688331","BK0057","CDE","LU1064130708.USD","000661","BK1574","BK0046","BK0188","LU2580892789.USD","LU1064131003.USD","LU2328871848.SGD","LU2488822045.USD","LU1328615791.USD","300122","09995","LU1223082196.USD","BK1583","BK4017","BK0077","BK0028","688506","LU1223083913.SGD","LU2148510915.USD","LU2580892862.HKD","BK0075","BK0239"],"gpt_icon":0},{"id":"2608886409","title":"股市必读：百利天恒（688506）预计2025年全年营业收入25亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608886409","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608886409?lang=zh_cn&edition=full","pubTime":"2026-02-02 02:33","pubTimestamp":1769970791,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，百利天恒报收于277.75元，下跌0.3%，换手率0.42%，成交量1.7万手，成交额4.8亿元。业绩披露要点业绩预告百利天恒发布业绩预告，预计2025年全年归属净利润亏损约11亿元；扣非后净利润亏损约12亿元；营业收入预计为25亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","02615"],"gpt_icon":0},{"id":"2607432016","title":"百利天恒：预计2025年净亏损11亿元 同比转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2607432016","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607432016?lang=zh_cn&edition=full","pubTime":"2026-01-30 18:02","pubTimestamp":1769767349,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月30日，百利天恒(688506.SH)公告称，预计2025年度归属于上市公司股东的净利润为-11.00亿元左右，上年同期为盈利37.08亿元，同比转亏。报告期内，公司持续加大研发投入，导致研发投入同比增幅较大。截至报告期末，公司共有17款创新药处于临床试验阶段（其中6款创新药处于全球临床试验）。公司正在全球范围内开展100余项创新药临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601303637105727.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303637105727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","02615","BK0239","91194"],"gpt_icon":0},{"id":"2606176278","title":"23股获推荐 百利天恒目标价涨幅超300%丨券商评级观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2606176278","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606176278?lang=zh_cn&edition=full","pubTime":"2026-01-27 09:09","pubTimestamp":1769476169,"startTime":"0","endTime":"0","summary":"南财投研通数据显示，1月26日，券商给予上市公司目标价共9次，按最新收盘价计算，目标价涨幅排名居前的公司有百利天恒、洛阳钼业、三七互娱，目标价涨幅分别为368.30%、37.88%、29.53%，分别属于化学制药、工业金属、游戏行业。从券商推荐家数来看，1月26日有23家上市公司得到券商推荐，其中建发股份、首华燃气、花园生物等获得1家推荐。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601273631460230.html","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601273631460230.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","02615","91194"],"gpt_icon":0},{"id":"2605054604","title":"百利天恒（688506）披露召开2026年第一次临时股东会通知，1月23日股价下跌0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605054604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605054604?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:20","pubTimestamp":1769178004,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，百利天恒报收于290.61元，较前一交易日下跌0.38%，最新总市值为1199.85亿元。该股当日开盘291.75元，最高294.99元，最低285.33元，成交额达5.94亿元，换手率为0.51%。近日，四川百利天恒药业股份有限公司发布《关于召开2026年第一次临时股东会的通知》。公告显示，公司定于2026年2月9日召开2026年第一次临时股东会，会议采取现场投票与网络投票相结合方式。股权登记日为2026年2月2日。股东可委托代理人出席。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","02615","BK0239"],"gpt_icon":0},{"id":"2605593460","title":"广发基金吴兴武旗下广发保健A年报最新持仓，重仓百利天恒","url":"https://stock-news.laohu8.com/highlight/detail?id=2605593460","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605593460?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:58","pubTimestamp":1769079533,"startTime":"0","endTime":"0","summary":"证券之星消息，1月22日广发基金旗下吴兴武管理的广发医疗保健股票型基金公布年报，近1年净值增长率16.73%。与上一季度相比，该基金前十大重仓股新增海思科，三生国健，信立泰；其中百利天恒持仓占比7.26%，为该基金第一大重仓股；新诺威，百济神州，一品红等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200033876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","688506","02615"],"gpt_icon":0},{"id":"2605170450","title":"1月21日百利天恒现269.67万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2605170450","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605170450?lang=zh_cn&edition=full","pubTime":"2026-01-21 17:41","pubTimestamp":1768988509,"startTime":"0","endTime":"0","summary":"证券之星消息，1月21日百利天恒发生大宗交易，交易数据如下：大宗交易成交价格303元，成交0.89万股，成交金额269.67万元，买方营业部为中信证券华南股份有限公司广州琶洲宸悦路证券营业部，卖方营业部为中国国际金融股份有限公司北京建国门外大街证券营业部。近三个月该股共发生3笔大宗交易，合计成交310.0手。截至2026年1月21日收盘，百利天恒报收于303.0元，下跌0.33%，换手率0.32%，成交量1.28万手，成交额3.89亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100029704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","02615","BK0239","91194"],"gpt_icon":0},{"id":"2604185671","title":"百利天恒iza-bren用于治疗复发性或转移性食管鳞癌的药品上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2604185671","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604185671?lang=zh_cn&edition=full","pubTime":"2026-01-20 20:14","pubTimestamp":1768911252,"startTime":"0","endTime":"0","summary":"百利天恒iza-bren用于治疗复发性或转移性食管鳞癌的药品上市申请获得受理","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601203624898124.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203624898124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","688506","BK0239","91194"],"gpt_icon":0},{"id":"2604906375","title":"贵州茅台等191股获推荐，百利天恒目标价涨幅超300%丨券商评级观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2604906375","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604906375?lang=zh_cn&edition=full","pubTime":"2026-01-19 09:53","pubTimestamp":1768787617,"startTime":"0","endTime":"0","summary":"21财经1月19日电，南财投研通数据显示，1月12日至1月18日，券商给予上市公司目标价共92次，按最新收盘价计算，目标价涨幅排名居前的公司有百利天恒、湖南裕能、华立科技，目标价涨幅分别为319.47%、85.81%、58.27%，分别属于化学制药、电池、文娱用品行业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601193623000868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03189","02615","688506","83189","91194","600519"],"gpt_icon":0},{"id":"2604749925","title":"每周股票复盘：百利天恒（688506）股东OAP拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2604749925","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604749925?lang=zh_cn&edition=full","pubTime":"2026-01-18 04:38","pubTimestamp":1768682289,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，百利天恒报收于315.16元，较上周的343.9元下跌8.36%。公司公告汇总四川百利天恒药业股份有限公司关于持股5%以上股东减持股份计划公告截至公告披露日，OAP III Limited持有公司6.91%股份，计划自公告披露之日起十五个交易日后三个月内，通过集中竞价方式减持不超过公司总股本1.00%的股份，即不超过4,128,738股，减持原因为自身资金需求。本次减持计划符合相关法律法规及承诺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","BK0239","688506","02615"],"gpt_icon":0},{"id":"2603492998","title":"百利天恒股东OAP III(HK)Limited拟减持不超1%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2603492998","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603492998?lang=zh_cn&edition=full","pubTime":"2026-01-16 19:54","pubTimestamp":1768564470,"startTime":"0","endTime":"0","summary":"1月16日，百利天恒（688506）发布公告，股东OAPIII(HK)Limited因自身资金需求，计划自公告披露之日起15个交易日后的三个月内，通过集中竞价方式减持不超过413万股公司股份，占公司总股本的1%。2025年前三季度，百利天恒实现收入20.66亿元，归母净利润-4.95亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601163622097950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","III","688506","BK4134","02615","91194"],"gpt_icon":0},{"id":"2602536916","title":"每周股票复盘：百利天恒（688506）EGFR×HER3双抗ADC纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2602536916","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602536916?lang=zh_cn&edition=full","pubTime":"2026-01-11 03:57","pubTimestamp":1768075027,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，百利天恒报收于343.9元，较上周的323.1元上涨6.44%。本周关注点公司公告汇总：iza-bren用于治疗食管鳞癌被纳入优先审评程序。公司公告汇总四川百利天恒药业股份有限公司自主研发的注射用iza-bren被国家药品监督管理局药品审评中心纳入优先审评品种名单，适用于既往经PD-1/PD-L1单抗联合含铂化疗治疗失败的复发性或转移性食管鳞癌患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","688506","91194","BK0239"],"gpt_icon":0},{"id":"2601363384","title":"百利天恒：首次回购14858股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601363384","media":"南方财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601363384?lang=zh_cn&edition=full","pubTime":"2026-01-08 18:48","pubTimestamp":1767869297,"startTime":"0","endTime":"0","summary":"南财智讯1月8日电，百利天恒公告，2026年1月8日公司通过集中竞价交易方式首次回购公司股份14,858股，占公司总股本的比例为0.0036%，回购成交的最高价为341.05元/股，最低价为332.81元/股，支付的资金总额为499.97万元（不含印花税、交易佣金等交易费用）。本次回购股份符合法律法规的规定及公司回购股份方案的要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601083612915036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688506","91194","02615"],"gpt_icon":0},{"id":"2601872229","title":"百利天恒：关于取得金融机构股票回购专项贷款承诺函的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2601872229","media":"证券日报","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601872229?lang=zh_cn&edition=full","pubTime":"2026-01-07 19:11","pubTimestamp":1767784284,"startTime":"0","endTime":"0","summary":"证券日报网讯1月7日，百利天恒发布公告称，近日，公司取得中国银行股份有限公司四川省分行出具的《贷款承诺函》，主要内容如下：1、贷款承诺额度：不超过1.8亿元人民币。2、贷款期限：3年。3、贷款用途：专项用于回购公司股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601073611616331.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["FISI","BK0239","91194","688506","02615","BK4211"],"gpt_icon":0},{"id":"2601186053","title":"百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于治疗复发性或转移性食管鳞癌被纳入优先审评程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2601186053","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601186053?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:53","pubTimestamp":1767689624,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，近日，公司自主研发的全球首创(First-in-class)、新概念(New concept)且唯一进入III期临床阶段的EGFR×HER3双抗ADC(注射用iza-bren)被国家药品监督管理局药品审评中心(简称“CDE”)纳入优先审评品种名单。根据公开资料查询，iza-bren也是全球首个被纳入优先审评品种名单的EGFR×HER3双抗ADC。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","02615","BK4080","688506","91194","BK0239","BK4231"],"gpt_icon":0},{"id":"2601855752","title":"百利天恒（688506）2.98亿股限售股将于1月6日解禁，占总股本72.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601855752","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601855752?lang=zh_cn&edition=full","pubTime":"2026-01-06 08:11","pubTimestamp":1767658269,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，百利天恒于1月6日将有2.98亿股限售股份解禁，为公司首发原股东限售股份，占公司总股本72.2%。最近一年内，该股累计解禁1244.01万股，占总股本的3.01%。本次解禁后，公司还有1187.38万股限售股份，占总股本2.88%。百利天恒主营业务：药品的研发、生产与营销。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600006230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","91194","BK0239","688506"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770884441120,"stockEarnings":[{"period":"1week","weight":0.062},{"period":"1month","weight":-0.1512},{"period":"3month","weight":-0.2151},{"period":"6month","weight":-0.0543},{"period":"1year","weight":0.546},{"period":"ytd","weight":-0.0963}],"compareEarnings":[{"period":"1week","weight":0.0073},{"period":"1month","weight":-0.008},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1177},{"period":"1year","weight":0.2453},{"period":"ytd","weight":0.0411}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"5979人(较上一季度增加25.08%)","perCapita":"67068股","listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","registeredCapital":"41287万元","survey":" 四川百利天恒药业股份有限公司的主营业务是创新生物药业务板块和化药制剂、中成药制剂业务板块。公司的主要产品是丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。","listedPrice":24.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}